

PCAB fee schedule - <http://www.pcab.info/fees.shtml>

The current annual fees are:

- 1 to 15 compounded Rx preparations /day: = \$1,250.00 / year
- 16 to 100 compounded Rx preparations/day = \$2,500.00 / year
- over 100 compounded Rx preparations/day = \$5,000.00 / year

NOTE: A pharmacy's annual supporting fee is based on the number of prescription preparations compounded on the average day. The figure is calculated using a five-day week and averaged by the year. A pharmacy can calculate its annual fee, and thus the amount it must pay to begin the accreditation process, by dividing the total of compounded prescription per year by 262 days.

Surveyor Expense

In addition to the annual fee the pharmacy must pay the expenses of the surveyor for the on-site or in-pharmacy survey. These expenses cover travel, either by automobile or air; hotel expenses; meals and such usual and customary expenses a surveyor might incur in the process of visiting your pharmacy. The amount, of course, will depend on the costs in your area.

Pertinent section of Colorado HB 07-1289

12-22-120. Registration of facilities.

(9) (a) SUBJECT TO PARAGRAPH (b) OF THIS SUBSECTION (9), A PRESCRIPTION DRUG OUTLET¹ MAY REGISTER AS A COMPOUNDING PRESCRIPTION DRUG OUTLET.

(b) NO FACILITY SHALL BE REGISTERED AS A COMPOUNDING PRESCRIPTION DRUG OUTLET UNLESS:

(I) THE FACILITY HAS BEEN ACCREDITED BY A BOARD-APPROVED COMPOUNDING ACCREDITATION ENTITY TO BE WITHIN ACCEPTABLE PARAMETERS TO COMPOUND MORE THAN TEN PERCENT OF THE FACILITY'S TOTAL SALES; AND

(II) OWNERSHIP OF THE FACILITY IS VESTED SOLELY IN A PHARMACIST.

(c) TO BE APPROVED BY THE BOARD TO ACCREDIT A COMPOUNDING PRESCRIPTION DRUG OUTLET, A COMPOUNDING ACCREDITATION ENTITY SHALL BE, AT A MINIMUM, A SCIENTIFIC ORGANIZATION WITH EXPERTISE IN COMPOUNDING MEDICATIONS.

¹ The term "Prescription drug outlet" means any pharmacy outlet registered pursuant to this article where prescriptions are compounded and dispensed. "PRESCRIPTION DRUG OUTLET" INCLUDES, WITHOUT LIMITATION, A COMPOUNDING PRESCRIPTION DRUG OUTLET REGISTERED PURSUANT TO SECTION 12-22-120 (9). Colorado Revised Statute 12-22-102 (30.2) as amended by HB 07-1289.

H-120.945 American Medical Association Action on Non FDA-Approved Compounded Medications (2006)

Our AMA:

1. recognizes that compounding pharmacies must comply with current United States Pharmacopeia and National Formulary (USP-NF) compounding monographs, when available, and recommends that they be required to conform with USP-NF General Chapters on pharmaceutical compounding to ensure the uniformity, quality, and safety of compounded medications;
2. recognizes the accreditation program of the Pharmacy Compounding Accreditation Board (PCABTM) and the PCABTM Seal of Accreditation as a means to identify compounding pharmacies that adhere to quality and practice standards, including those set forth in the USP-NF, for the preparation of individualized medications for specific patients;
3. encourages all state boards of pharmacy to require compounding pharmacies in their states to obtain the PCABTM Seal of Accreditation or, alternatively, to satisfy comparable standards that have been promulgated by the state in its laws and regulations governing pharmacy practice; and
4. encourages state boards of pharmacy and the National Association of Boards of Pharmacy (NABP), the umbrella organization for state boards of pharmacy, to work with the United States Food and Drug Administration (FDA) to identify and take appropriate enforcement action against entities that are illegally manufacturing medications under the guise of pharmacy compounding. (BOT Action in response to referred for decision Res. 521, A-06)

The following policy was adopted by the 2008 APhA House of Delegates and is now official Association policy:

Pharmacy Compounding Accreditation

1. APhA reaffirms the 1992 Compounding Activities of Pharmacists policy, which states that APhA affirms that compounding pursuant to or in anticipation of a prescription or diagnostic preparation order is an essential part of health care that is the prerogative of the pharmacist.
2. APhA supports compounding as defined by the Pharmacy Compounding Accreditation Board (PCAB) as a means to meet patient drug therapy needs.
3. APhA opposes compounding when identical medications are commercially and readily available in strength and dosage form to meet patient drug therapy needs.
4. APhA asserts that compounding is subject to regulations and oversight from state boards of pharmacy. APhA urges state boards of pharmacy to identify and take appropriate action against entities who are illegally manufacturing medications under the guise of compounding.
5. APhA supports accreditation of compounding sites by PCAB to ensure patient safety. APhA encourages state boards of pharmacy to recommend accreditation for those sites that engage in more than basic non sterile compounding as defined by PCAB.
6. APhA supports the development of education, training and recognition programs that enhance pharmacist and student pharmacist knowledge and skills to engage in compounding beyond basic, non sterile preparations as defined by PCAB.
7. APhA encourages the exploration of a specialty certification in the area of compounding through the Board of Pharmaceutical Specialties (BPS)